Association of Asprosin in Periodontitis and Acute Coronary Syndrome

Completed

• Conditions: Cardiovascular Diseases; Periodontal Diseases
• Interventions: Diagnostic Test: Serum samples will be collected. Asprosin levels will be determined by biochemical analysis

• Registration Number: NCT05647902
• Lead Sponsor: Ataturk University

Brief Summary

Asprosin, a recently discovered glucogenic adipokine, is mainly synthesized by white adipose tissue and released during fasting. Appetite, glucose metabolism, insulin resistance, cell apoptosis, etc. asprosin is associated with diseases such as diabetes, obesity, polycystic ovary syndrome, and cardiovascular diseases. Periodontal tissue may act as a source of endocrine-like inflammatory mediators (such as TNF-α, IL-6 and IL-1) that are important in periodontal inflammation and can affect glucose and lipid metabolism. Production of TNF-α and IL-6 in adipose tissues strengthens the relationship between cardiovascular diseases and periodontitis. Investigators postulated that asprosin may be a candidate for explaining the triangular relationship between cardiovascular and periodontal disease.

Detailed Description

Periodontal disease is a chronic, multifactorial, and infectious disease caused by bacteria. It is characterized by the formation of an inflammatory response in the supporting bone and connective tissue against microbial dental plaque, and the nature of the resulting inflammatory response determines the course of periodontal disease. Cardiovascular and periodontal diseases are closely related, presenting a triad association. Asprosin circulates in the blood at nanomolar levels and is taken to the liver, where it activatesinvestigators the G protein-cAMP-PKA pathway, causing rapid glucose release into the circulation.

Study Timeline

• Study Start: 2022-01-01
• Study First Submitted: 2022-12-04
• Study First Submitted QC: 2022-12-04
• Study First Posted: 2022-12-13
• Primary Completion: 2022-12-30
• Study Completion: 2023-01-01
• Status Verified: 2023-07
• Last Update Submitted: 2023-07-19
• Last Update Posted: 2023-07-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

For Healthy group

• All individuals were generally healthy,
• non-smoking For Myocard Infarctus group
• patients with ST elevation of Myocardial Infactus
• patient with less than ten teeth

Exclusion Criteria

• Smokers or those with diabetes or other inflammatory disease
• Pregnant or breastfeeding women
• None had undergone periodontal therapy and/or antibiotic therapy in the past 6 months.
• None has a contagious disease such as HIV or AIDS

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Myocard Infactus Group	Serum samples will be collected. Asprosin levels will be determined by biochemical analysis	50 patients with myocardial infarction; 25 healthy gingiva is divided into 2 subgroups, 25 of which are periodontitis. Asprosin levels will be examined biochemically in serum samples taken from patients.
Healthy Group	Serum samples will be collected. Asprosin levels will be determined by biochemical analysis	70 systemically healthy patients; 35 healthy gingiva is divided into 2 subgroups, 35 of which are periodontitis. Asprosin levels will be examined biochemically in serum samples taken from patients.

Primary Outcome Measures

Name	Time	Method
Asprosin Levels	two weeks	Determination of asprosin levels by making biochemical analyzes from serum

Trial Locations

Locations (1)

Atatürk University Faculty of Dentistry; 🇹🇷 Erzurum, Turkey